Selective COX-2 inhibitors, eicosanoid synthesis and clinical outcomes: A case study of system failure

Lipids

Volumn 42, Issue 9, 2007, Pages 779-785

  James, M J ^a   Cook Johnson, R J ^a   Cleland, L G ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

COX 2; Eicosanoids; Ethics; Rofecoxib; Vioxx

Indexed keywords

DRUG DOSAGE; FAILURE ANALYSIS; ONCOLOGY; PATIENT TREATMENT;

BIOLOGICAL MECHANISMS; COLORECTAL CANCER; COX-2 INHIBITORS; NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS);

ENZYME INHIBITION;

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; ICOSANOID; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; ROFECOXIB; VALDECOXIB;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; FATTY ACID SYNTHESIS; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; MEDICAL ETHICS; MEDICAL LITERATURE; PEPTIC ULCER BLEEDING; THROMBOSIS; ULCER; ULCER PERFORATION;

CARDIOVASCULAR SYSTEM; CYCLOOXYGENASE 2 INHIBITORS; DRUG EVALUATION; EICOSANOIDS; HUMANS; RISK FACTORS;

EID: 35348831174     PISSN: 00244201     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11745-007-3069-x     Document Type: Conference Paper

References (42)

1. Moncada S, Ferreira SH, Vane JR (1975) Inhibition of prostaglandin biosynthesis as the mechanism of analgesia of aspirin-like drugs in the dog knee joint. Eur J Pharmacol 31:250-260
2. Vane JR, Bakhle YS, Botting RM (1998) Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38:97-120
3. Fries JF, Murtagh KN, Bennett M, Zatarain E, Lingala B, Bruce B (2004) The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 50:2433-2440
4. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K, Isakson PC, Stallings WC (1996) Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384:644-648
5. Hawkey CJ (1999) COX-2 inhibitors. Lancet 353:307-314
6. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 96:7563-7568
7. Demasi M, Cleland LG, Cook-Johnson RJ, Caughey GE, James MJ (2003) Effects of hypoxia on monocyte inflammatory mediator production: dissociation between changes in cyclooxygenase-2 expression and eicosanoid synthesis. J Biol Chem 278:38607-38616
8. Caughey GE, Cleland LG, Penglis PS, Gamble JR, James MJ (2001) Roles of cyclooxygenase (COX) -1 and -2 in prostanoid production by human endothelial cells: selective upregulation of prostacyclin synthesis by COX-2. J Immunol 167:2831-2838
9. Cook-Johnson RJ, Demasi M, Cleland LG, Gamble JR, Saint DA, James MJ (2006) Endothelial cell COX-2 expression and activity in hypoxia: transcriptional control mechanisms. BBA-Cell Mol Biol Lipids 1761:1443-1449
10. 2. J Biol Chem 276:37839-37845
11. 2 production in human monocytes: implications for the use of cyclooxygenase inhibitors. J Immunol 165:1605-1611
12. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ, Fitzgerald GA (1999) Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 289:735-741
13. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, Fitzgerald GA (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96:272-277
14. Stemme V, Swedenborg J, Claesson H-E, Hansson GK (2000) Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries. Eur J Vasc Endovasc Surg 20:146-152
15. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ (2000) Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102:840-845
16. Baker CS, Hall RJ, Evans TJ, Pomerance A, Maclouf J, Creminon C, Yacoub MH, Polak JM (1999) Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol 19:646-655
17. Topper JN, Cai J, Falb D, Gimbrone MA (1996) Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 93:10417-10422
18. Dowd NP, Scully M, Adderley SR, Cunningham AJ, Fitzgerald DJ (2001) Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 108:585-590
19. Adderley SR, Fitzgerald DJ (1999) Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J Biol Chem 274:5038-5046
20. Bolli R, Shinmura K, Tang XL, Kodani E, Xuan YT, Guo Y, Dawn B (2002) Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res 55:506-519
21. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353:2373-2383
22. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS (2000) Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial, Celecoxib long-term arthritis safety study. JAMA 284:1247-1255
23. US Food and Drug Authority (accessed April 2007) FDA Advisory Committee briefing document. NDA 20-998/S-009. Celebrex capsules (Celecoxib). Medical Officer Review. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_03_med. doc
24. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355:873-884
25. US Food and Drug Authority (accessed April 2007) FDA Advisory Committee briefing document. NDA 21-042, s007. VIOXX gastrointestinal safety. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_03_med.pdf
26. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, Weaver A (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343:1520-1528
27. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092-1102
28. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352:1081-1091
29. McGettigan P, Henry D (2006) Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296:1633-1644
30. Couzin J (2004) Drug safety: withdrawal of vioxx casts a shadow over COX-2 inhibitors. Science 306:384-385
31. Juni P, Rutjes AWS, Dieppe PA (2002) Are selective COX-2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? Br Med J 324:1287-1288
32. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR (2002) Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 359:118-123
33. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR (2002) COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 360:1071-1073
34. Merck & Co (accessed April 2007) Annual Report. 2001-04. http://phx.corporate-ir.net/phoenix.zhtml?c=73184&p=irol-reportsannual
35. Lexchin J (2002) Should doctors be prescribing new drugs? Int J Risk Safety Med 15:213-222
36. National Institute for Health Care Management (accessed April 2007) Prescription Drugs and Mass Media Advertising, 2000. http://www.nihcm.org/ finalweb/DTCbrief2001.pdf
37. Waxman HA (accessed April 2007) Statement of Rep. Henry A. Waxman for the hearing "The role of FDA and pharmaceutical companies in ensuring the safety of approved drugs, like Vioxx." http://democrats.reform.house.gov/ Documents/20050505113149-41995.pdf
38. Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ (2001) Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 104:2280-2288
39. Topol EJ (2004) Failing the public health-rofecoxib, Merck, and the FDA. N Engl J Med 351:1707-1709
40. Mukherjee D, Nissen SE, Topol EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954-959
41. Cleland LG, James MJ, Stamp LK, Penglis PS (2001) COX-2 inhibition and thrombotic tendency: a need for surveillance. Med J Aust 175:214-217
42. Graham DJ (accessed April 2007) Testimony of Dr David Graham, US Senate Committee on Finance. http://www.senate.gov/~finance/hearings/testimony/ 2004test/111804dgtest.pdf